For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one.
Although motor fluctuations in Parkinson’s disease (PD) can be managed effectively in early stages of the disease, today’s treatment paradigm is suboptimal owing to considerable pill burden, a risk of motor and nonmotor complications associated with dopaminergic therapy, and a progressive loss of efficacy. In response, the pipeline for therapies targeting motor fluctuations has swelled. With the recent launch of first-in-class A2A receptor antagonist Nourianz, as well as other newer-to-market brands like Xadago and Ongentys, understanding the drivers of clinical decision-making for treating motor fluctuations and prescriber perceptions of approved options will help innovators identify levers for new product positioning and differentiation in this evolving market niche.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 U.S. and 30 European neurologists fielded in April and May 2021.
Key companies: UCB, Neurocrine Biosciences / Bial, Newron / Zambon / Supernus, KHK, AbbVie, Cerevel Therapeutics.
Key drugs: Neupro (transdermal rotigotine), Xadago (safinamide), Ongentys (opicapone), Nourianz (istradefylline).
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.